Medtronic offers a 7 percent discount to push 80.1% of MiniMed onto its own shareholders

MedDevice Startups Staff · 3 days ago · 2 min read · Via MassDevice

Medtronic launched an exchange offer on September 14 covering 80.1% of MiniMed's outstanding common stock. Shareholders who tender Medtronic stock get roughly $107.53 in MiniMed shares for every $100 they hand in, a 7 percent discount. The offer runs through October 9.

MiniMed listed on Nasdaq as MMED in March and raised about $538 million net. Medtronic held roughly 90 percent afterward, more than 252.8 million shares. The stock traded at $21.50 on the day of the announcement, up about 18 percent since the IPO. If the offer is oversubscribed, Medtronic can move the rest of its stake.

CEO Geoff Martha said the separation lets Medtronic put capital behind its cardiovascular, neuroscience and surgical portfolios. MiniMed CEO Que Dallara said it "gives us complete autonomy over our capital allocation, our product roadmap, and our speed."

For anyone building in diabetes, the practical change is budget authority. A standalone MiniMed sets its own spend on the patch pump and insulin-calculation algorithm it has already filed, without those programs competing internally against cardiac ablation.

Questions & Answers

What is Medtronic's MiniMed exchange offer?

On September 14, 2026 Medtronic launched an exchange offer covering 80.1% of MiniMed's outstanding common stock. Medtronic shareholders who tender receive about $107.53 in MiniMed stock for every $100 of Medtronic stock, a 7 percent discount, and the offer expires October 9, 2026.

When did MiniMed go public and how much did the IPO raise?

MiniMed listed on Nasdaq under the ticker MMED in March 2026 and raised about $538 million in net proceeds. Medtronic kept roughly 90 percent of the company, more than 252.8 million shares.

Why is Medtronic separating MiniMed?

Medtronic CEO Geoff Martha said the separation lets Medtronic focus capital on its cardiovascular, neuroscience and surgical portfolios. MiniMed CEO Que Dallara said it gives MiniMed autonomy over its capital allocation, product roadmap and speed.

← Back to M&A